http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015520220-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
filingDate | 2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2015-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2015520220-A |
titleOfInvention | Cycloalkyl ether compounds and their use as BACE inhibitors |
abstract | For diseases such as cycloalkyl ether compounds, therapeutically acceptable salts thereof, processes for producing them, Down syndrome, β-amyloid angiopathy, Alzheimer's disease, forgetfulness, attention deficit symptoms related to Alzheimer's disease, Alzheimer's disease Related neurodegeneration or dementia, including mixed vascular and degenerative origin, presenile dementia, senile dementia, and dementia related to Parkinson's disease, progressive supranuclear palsy, or cortical basal degeneration Therapeutic use of these compounds to treat Aβ-related pathologies such as disease, as well as pharmaceutical compositions containing such compounds. Formula (I), wherein A is —O— or —CH 2 —, and n is 0 or 1. [Chemical 1] |
priorityDate | 2012-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 278.